Non-selective beta-blockers (NSBBs) are the mainstay of treatment for portal hypertension in
the setting of liver cirrhosis. Randomised controlled trials demonstrated their efficacy in …

Managing liver cirrhosis in clinical practice is still a challenging problem as its progression is
associated with serious complications, such as variceal bleeding that may increase …

Background Clinical decompensation of cirrhosis is associated with poor prognosis.
Clinically significant portal hypertension (CSPH), defined by a hepatic venous pressure …

Background & Aims Whether non-selective β-blockers can prevent decompensation of
cirrhosis warrants clarification. Carvedilol might be particularly effective since its intrinsic …

This guidance provides a data-supported approach to risk stratification, diagnosis, and
management of patients with cirrhosis and portal hypertension (PH). A guidance document …

Portal hypertension (PH) is the most common complication ofcirrhosis and represents the
main driver of hepatic decompensation. The overarching goal of PH treatments in patients …

Diese interdisziplinäre Leitlinie unter Leitung der DGVS und Beteiligung benachbarter
Fachgesellschaften fasst die wichtigsten Aspekte zur Versorgung von Patienten mit …

Clinically significant portal hypertension is associated with an increased risk of developing
gastro-oesophageal varices and hepatic decompensation. Hepatic venous pressure …

Bleeding from gastroesophageal varices is a serious complication in patients with liver
cirrhosis and portal hypertension. Although there has been significance improvement in the …

Clin Mol Hepatol Volume_26 Number_2 April 2020 https://doi. org/10.3350/cmh. 2019.0010
n clinical practice. Therefore, these revised guidelines for the treatment of varices and HE …